| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Evotec SE$2.79
-0.05 (-1.94%)
D 37Pipeline Score Tools & Services · Commercial
Market Cap
1.09 B
EPS
-0.33
P/E Ratio
-9.47 $
Value Trade
67.87 K
-8.81 %
Week
22.95 %
1 Month
-20 %
3 Month
-27.01 %
6 Month
-85.65 %
5 Year
-85.65 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
31.02 K
52 Week Range
2.31 - 4.80
% held by Insiders
5.17 %
% held by Institutions
1 %
Enterprise Value
1.06 B
Total Shares
355.18 M
Short %
0.02 %
Float Shares
336.82 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Evotec SE
5Total events
0Upcoming
2Tier-1 (high impact)
2025 – 2026Coverage
Event history 5
Jun 30, 2026
Jun 30, 2026
▲Product LaunchJ.TRAINPost-Market
Launch of J.TRAIN turnkey continuous manufacturing offering
Apr 2026
Dec 2025
Drug Pipeline Intelligence
D37
Pipeline Score $297M
Pipeline ValueValuation Signal
5
Drugs Scored0.3x
rNPV / MCap Top 52%
Micro Cap (rank 438 of 911)
Percentile RankEvotec SE faces pipeline headwinds (37/100), with $948M risk-adjusted pipeline value, led by EVT 302, in Smoking Cessation (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EVT 302, Small molecule | Smoking Cessation | Phase 2 | NCT00622752 | 14% | $436M | COMPLETED | 490 | - | - | May 1, 2008 | - | Jun 17, 2008 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EVO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EVO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EVOJust - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
Evotec SE has launched J.TRAIN, a new continuous manufacturing platform for biopharmaceutical companies. This technology enables partners to deploy advanced manufacturing capabilities directly in their facilities, enhancing productivity and reducing costs. With modular cleanroom designs and rapid implementation timelines, J.TRAIN represents a significant advancement over traditional manufacturing methods.
Read more →EVOJust – Evotec Biologics Launches J.TRAIN to Deliver Turnkey ...
Evotec SE has expanded its Just – Evotec Biologics services by launching J.TRAIN, a new offering that allows biopharmaceutical companies to implement Evotec's continuous manufacturing technology in their facilities. This service combines modular cleanrooms and standard manufacturing equipment with cGMP-compliant process automation, promising quicker and more economical deployment compared to traditional methods.
Read more →EVODirectors' Dealings | 16 June 2026 17:46 Notification and public disclosure of transactions by persons discharging manageri responsibilities and persons closely associated with them 16.06.2026 / 17:45 CET/CEST The issuer
On June 15, 2026, Cord Dohrmann, a member of the managing body at Evotec SE, disposed of shares amounting to 576,720 EUR at a price of 4.81 EUR per share. The transaction raises potential concerns among investors regarding management's confidence in the company's future prospects. The trade was conducted on the Xetra trading platform and has been disclosed following regulatory requirements.
Read more →EVOEvotec Reports Results of the Annual General Meeting 2026
Evotec SE held its Annual General Meeting where all agenda items were approved by shareholders. Dieter Weinand and Dr. Wolfgang Hofmann were newly elected to the Supervisory Board, with Weinand appointed as Chairman. Additionally, Dr. Duncan McHale and Wesley Wheeler were re-elected. A total of 43.10% of registered share capital was represented at the meeting.
Read more →EVOEvotec Appoints Rui Wang as Head of Global In Silico and AI
Evotec SE has appointed Rui Wang as Executive Vice President, Head of Global In Silico and AI. With over 20 years of experience, Wang will lead the integration of AI and computational science into Evotec's R&D operations. CEO Christian Wojczewski emphasized the importance of advanced computational tools in enhancing operational efficiency and innovation within the company.
Read more →EVOEvotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
Evotec has announced the nomination of a small molecule preclinical development candidate in collaboration with Almirall, aimed at treating immune-mediated inflammatory skin diseases. The program has progressed significantly faster than industry standards, showcasing Evotec's integrated AI/ML-driven R&D capabilities. The partnership aims to address high unmet medical needs in dermatology and will continue towards IND submission.
Read more →EVOFor further information, please contact : Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, sarah.fakih@evotec.com, M. +49.(0)151 70 688 784, www.evotec.com INTERIM STATEMENT 3M 2026 HIGHLIGHTS M
Evotec SE faced a challenging financial performance in the first quarter of 2026, with a 21.7% decrease in group revenue compared to the same period in 2025. The Discovery & Preclinical Development (D&PD) segment particularly struggled, reporting a 14.7% decline in revenues. Despite the financial downturn, the company demonstrated progress in strategic partnerships and advancements in organizational transformation. Reorganization costs related to the Project Horizon initiative significantly impacted overall financial results.
Read more →EVOEvotec SE to Announce First Quarter 2026 Results on May 6, 2026
Evotec SE will announce its first quarter 2026 financial results on May 6, 2026. The announcement will be accompanied by a business update during a webcast and conference call. Participants can register for the event to access presentation slides and join the audio call. Evotec continues to emphasize its role in drug discovery and development.
Read more →EVOEvotec Announces New Nomination to Board of Directors Nomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilities Conclusion of cooperation agree
Evotec SE has announced the nomination of Dr. Wolfgang Hofmann as an independent member of its Supervisory Board at the upcoming AGM. This nomination, along with Dieter Weinand's election as Chairman, aims to strengthen governance expertise within the board. Additionally, Evotec has entered a cooperation agreement with key shareholder MAK Capital, emphasizing their commitment to constructive engagement and long-term corporate success. The announcements align with Evotec's strategy to enhance shareholder value through strengthened oversight.
Read more →EVOEvotec Announces Chief Financial Officer Transition Paul Hitchin to step down as of
Evotec SE has announced a transition in its financial leadership with Chief Financial Officer Paul Hitchin set to step down on April 30, 2026, for personal reasons. He will be succeeded by Claire Hinshelwood, who has extensive experience in financial roles, including positions at BMI Group and Novartis. The company acknowledges Hitchin's substantial contributions during his tenure and expresses confidence in Hinshelwood's ability to guide Evotec towards a new phase of growth and profitability. This leadership change is positioned as a continuation of Evotec's efforts to transform its operations and financial performance.
Read more →EVOEvotec Announces Fourth Quarter and Full-Year 2025 Results: Foundation for Profitable Growth 2025 financial performance at high end of guidance: Q4 and FY group revenues of 253.3 m and 788.4 m, respectively (Q4: 266.7 m,
Evotec SE reported strong financial performance for Q4 and the full year of 2025, with revenues reaching €253.3 million for the quarter and €788.4 million for the year. The results align with the upper limit of the company's guidance and reflect robust activity within strategic partnerships. A new operating model, Horizon, is set to support further growth by streamlining operations and enhancing commercial capabilities. Leadership changes are expected to bolster Evotec's ability to rapidly respond to market demands.
Read more →EVOEvotec Nominates Dieter Weinand as Supervisory Board Chairman Strengthens Supervisory Board leadership to support Evotec's transformation, with a focus on commercial execution, strategic partnerships and profitability In
Evotec SE has announced the nomination of Dieter Weinand as the new Chairman of the Supervisory Board, set to be elected at the Annual General Meeting on June 11, 2026. Weinand, who has a strong background in the pharmaceutical industry, succeeds Prof. Dr. Iris L w-Friedrich as part of a planned succession. His appointment aims to bolster Evotec's strategic execution and partnerships as the company seeks to enhance its value and profitability. Evotec emphasizes its role in the biopharma ecosystem and aims to leverage Weinand's expertise to achieve its strategic goals.
Read more →EVO▼ -11.9%on this news· ran to -24% by day 3
Evotec Announces Horizon' - Next Inflection in Its Strategic Transformation to Accelerate Growth and Promote Agility Horizon advances multi-stage transformation initiated with Priority Reset in 2024 and establishes new o
Evotec SE announced its Horizon initiative, aimed at streamlining operations and enhancing agility through a multi-stage transformation. This new operating model focuses on three pillars: operations, science, and commercial execution, and anticipates approximately 75 million in run-rate savings by 2027. The company plans to reduce its global footprint from 19 to 10 sites, potentially affecting up to 800 jobs. The implementation of Horizon is expected to provide a clearer framework for operational excellence and improved profitability through 2030.
Read more →EVONotification of Major Holdings Page 1 | 5 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name,
Evotec SE has received a notification regarding major holdings from Goldman Sachs Group, Inc., indicating a change in voting rights. The notification details the voting rights attached to shares, as well as rights to various financial instruments related to the company's stock. After the general meeting, the total voting rights represented by shares and instruments are listed alongside respective percentages. This update reflects adherence to regulatory requirements regarding significant shareholder transactions.
Read more →EVOStimmrechtsmitteilung Seite 1 | 5 Hamburg 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Stimmrechtsmitteilung oder Korrektur einer Stimmrechtsmitteilung vom 1. Angaben zum Emittenten Name
The article details a shareholder notification regarding voting rights held by Michael Kaufman and his affiliated entities, which collectively hold a 5.03% stake in Evotec SE. The report outlines specific percentages of voting rights attributed to various investment instruments, including equity swaps. This information is part of regulatory disclosure mandates in Germany, ensuring transparency regarding significant shareholders' voting power in the company. The report includes details about voting rights percentages and the structure of associated entities, without indicating any immediate positive or negative implications for the company.
Read more →EVOJust - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modali
Just - Evotec Biologics has received a grant from the Gates Foundation aimed at improving the developability and affordability of monoclonal antibodies. The funding will be used to implement ten new projects over the next three years that focus on addressing global health challenges. By leveraging advanced computational technologies, the company aims to streamline biotherapeutics development, making treatments more accessible in low- and middle-income countries. This initiative extends Just - Evotec's long-standing commitment to enhancing healthcare access since 2014.
Read more →EVO▲ +5%on this newsshared move
Notification of Major Holdings Page 1 | 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name,
The notification from JPMorgan Chase & Co. reveals an increase in their holdings in Evotec SE, with total voting rights now at 5.51%. This increase includes both direct and indirect holdings, along with details regarding various financial instruments involved. The notification comes as part of regulatory compliance under the WpHG, indicating transparency in ownership stake.
Read more →EVOEvotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
Evotec SE has appointed Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations. This new role aims to integrate communications and investor relations, enhancing strategic messaging and stakeholder alignment. Dr. Fakih, with over 15 years of experience in life sciences, will report directly to CEO Dr. Christian Wojczewski.
Read more →EVONotification of Major Holdings Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Na
The article discusses a notification regarding major holdings by JPMorgan entities in Evotec SE. It details the voting rights associated with shares held by JPMorgan and outlines specific voting percentages and instruments related to their holdings. The communication also specifies the thresholds crossed regarding these holdings as of December 29, 2025. Overall, it serves as a formal report required by securities regulation.
Read more →EVOEvotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations Creation of new Executive Vice President role integrating Global Communications and Investor Relations to strengthen strategic
Evotec has appointed Dr. Sarah Fakih as the new Executive Vice President, Head of Global Communications and Investor Relations. This newly created role will integrate both functions to enhance alignment and clarity among stakeholders. Dr. Fakih, who has over 15 years of experience in life sciences and a strong background in capital markets strategy and corporate messaging, is expected to strengthen Evotec's communication strategy. This change comes following the departure of Volker Braun, who successfully managed the Investor Relations and ESG functions over the past five years.
Read more →EVOEvotec Closes Sale of Just - Evotec Biologics’ Toulouse Site to Sandoz
Evotec SE has successfully closed the sale of its Just - Evotec Biologics manufacturing site in Toulouse to Sandoz AG for approximately $350 million. The agreement includes potential additional payments exceeding $650 million and royalties on a portfolio of biosimilars. This strategic move aims to enhance Evotec's focus on technology monetization and transition to a more asset-light business model.
Read more →EVOAnnouncement pursuant to Article 5(1)(a) of Regulation (EU) No. 596/2014 in conjunction with Article 2(1) of Delegated Regulation (EU) No. 2016/1052 Hamburg, 6 November 2025 - The management board of Evotec SE (Frankfurt
Evotec SE has announced a share repurchase program, set to run from November 7 to December 17, 2025. The company plans to buy back up to 290,000 shares, totaling a purchase price of up to EUR 3,000,000. This initiative is designed to support the employee share program and will comply with relevant EU regulations. The transactions will be independently managed by a credit institution and will be publicly disclosed following execution.
Read more →EVO▼ -15.7%on this newsshared move
interim STATEMENT 9M 2025 HIGHLIGHTS CHANGE IN REVENUE MIX ALIGNED WITH NEW STRATEGY FOR LONG-TERM PROFITABLE GROWTH DEMAND IN THE DISCOVERY & PRECLINICAL DEVELOPMENT ("D&PD") SEGMENT STILL SOFT; JUST - EVOTEC BIOLOGICS
Evotec SE reported its financial highlights for the first nine months of 2025, indicating a decrease in group revenues by 7.1% compared to the same period in 2024, primarily driven by lower performance in the Discovery & Preclinical Development segment. In contrast, revenues from Just-Evotec Biologics saw an increase of 11.3% due to a strong order book. Despite successful cost reductions across various sectors, the gross margin faced a significant drop, impacted by ongoing market challenges and overcapacity in certain sectors. The company reaffirmed its financial guidance for the full year 2025.
Read more →EVO▼ -15.7%on this newsshared move
In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules Transaction showcases Evotec's unique
Evotec has entered into a significant agreement with Sandoz, which involves the sale of its Just - Evotec Biologics Toulouse site for approximately US$ 350 million in cash, along with potential additional revenues exceeding US$ 300 million from milestone payments. The deal includes royalties from a portfolio of up to ten biosimilars targeting a sizable market of over US$ 90 billion in originator net sales. Expected to be impactful in enhancing Evotec's revenue, profit margins, and overall capital efficiency, the transaction is set to close in Q4 2025, pending regulatory approvals.
Read more →EVOinterim STATEMENT 6M 2025 HIGHLIGHTS CHANGING REVENUE MIX ALIGNED WITH NEW STRATEGY FOR SUSTAINABLE PROFITABLE GROWTH NAME OF REPORTING SEGMENT UPDATED TO BETTER REFLECT STRATEGIC FOCUS: DISCOVERY & PRECLINICAL DEVELOPME
Evotec SE has reported its financial performance for the first six months of 2025, showcasing a decline in group revenues by 5.0% compared to the same period in 2024. The revenue drop was primarily due to a significant decrease in the Discovery and Preclinical Development segment, although Just - Evotec Biologics showed positive growth. The company confirmed its adjusted guidance for full-year 2025 amid ongoing strategic adjustments and cost management efforts. The overall operational losses have seen some improvement due to lower past reorganization costs.
Read more →EVODisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec SE and Sandoz AG planning potential sale of Just - Evotec Biologics Toulouse site Hamburg, Germany - Evotec SE
Evotec SE has signed a non-binding agreement with Sandoz AG regarding the potential sale of its Just - Evotec Biologics site in Toulouse, France, valued at around US$ 300 million. The transaction is expected to improve Evotec's revenue mix and profit margins while providing future economic benefits through development revenues and royalties. The completion of the deal is contingent on employee consultations, regulatory compliance, and final agreements.
Read more →EVO▼ -13.4%on this news
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec SE adjusts revenue guidance while confirming profit guidance Hamburg, Germany - Evotec SE (Frankfurt Stock Exch
Evotec SE has revised its revenue guidance for the fiscal year 2025, expecting revenues to fall between 760 million and 800 million euros, down from a previous estimate of 840 to 880 million euros. However, the company has maintained its profit guidance, with projections for R&D expenditures and adjusted EBITDA remaining unchanged. The adjustments are attributed to a change in revenue mix and significant cost savings. While the technology licensing sector is expected to strengthen, the Shared R&D business may experience difficulties in the second half of 2025.
Read more →EVOEvotec SE: Results of the Annual General Meeting 2025 All agenda items adopted Under the topic "Pioneering Drug Discovery" CEO Dr Christian Wojczewski presented Evotec's current situation and strategic outlook 46.45% of
Evotec SE announced the results of its 2025 Annual General Meeting, where shareholders approved all agenda items with a significant majority. The meeting, led by CEO Dr. Christian Wojczewski and other executives, focused on the company's strategic outlook and ongoing initiatives in drug discovery. Notably, the shareholders also confirmed the appointment of new management members and approved several resolutions regarding the remuneration system and auditor appointments. A total of 46.45% of registered share capital was represented in the meeting.
Read more →EVOFor further information, please contact: Volker Braun, EVP Head of Global Investor Relations & ESG, volker.braun@evotec.com, M. +49.(0)40 228 999 338, www.evotec.com interim STATEMENT 3M 2025 HIGHLIGHTS START TO THE YEAR
Evotec SE released its interim statement for the first three months of 2025, reporting a 4% decrease in group revenues compared to the same period in 2024. Revenue growth was observed in the Just-Evotec Biologics segment, but overall net income loss increased to 31.6 million euros. The Shared R&D segment faced challenges, leading to reduced revenue and profitability. The company continues to manage costs amid a restructuring phase while maintaining cash flow stability.
Read more →EVO▲ +10.1%on this news· ran to +25% by day 3
Evotec SE unveils new strategy and provides 2025 guidance bolstered by strong Q4 2024 results Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds
Evotec SE has unveiled a new strategic direction aimed at sustainable and profitable growth, bolstered by robust Q4 2024 financial results. The company has met its full year guidance, showcasing significant improvements in liquidity. CEO Dr. Christian Wojczewski emphasized a renewed focus on technology and science leadership, combining innovative platforms and AI to accelerate drug discovery. Evotec's 2025 guidance indicates a commitment to further growth and strategic partnerships, positioning the company favorably in the market.
Read more →EVO▲ +10.1%on this news· ran to +25% by day 3
Evotec announces change in Management Board Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025 Hamburg, Ge
Evotec SE announced a change in its Management Board as Laetitia Rouxel steps down as Chief Financial Officer effective February 28, 2025. Paul Hitchin has been appointed to succeed her beginning March 1, 2025. Rouxel joined Evotec in April 2023 and is leaving to pursue other opportunities, while Hitchin brings over 20 years of experience in finance leadership roles to the position. The company is optimistic about the leadership transition and its implications for future growth.
Read more →EVOEvotec announces change in Management Board Dr Craig Johnstone steps down as Chief Operating Officer effective 31 December 2024 Distribution of responsibilities internally Hamburg, Germany, 29 November 2024: Evotec SE (F
Evotec SE has announced that Dr. Craig Johnstone will step down as Chief Operating Officer effective December 31, 2024. During his 12-year tenure, he played a crucial role in shaping the company's global operations. The responsibilities of the COO will be redistributed internally until a new structure is established as part of a strategic review. Both management and the supervisory board have expressed their gratitude for his contributions and have wished him well in his future endeavors.
Read more →EVO▼ -16.1%on this news
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Comment on withdrawn non-binding offer Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime
Evotec SE has announced that Halozyme Therapeutics has withdrawn its non-binding proposal to acquire the company for EUR11.00 per share. The Evotec Management and Supervisory Boards are actively reviewing the proposal that was initially submitted on November 13, 2024. Despite the withdrawal, Evotec remains confident in its standalone strategy, which aims to boost growth and long-term profitability for its shareholders.
Read more →EVO▲ +6.7%on this news
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Comment on media report Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN
Evotec SE acknowledged receipt of a non-binding expression of interest from Halozyme Therapeutics Inc. for a potential takeover at EUR 11.00 per share. The company plans to evaluate this opportunity carefully and will inform the capital market following legal requirements. This interaction could signal strategic interest from larger firms in Evotec.
Read more →EVO▼ -15.6%on this news
For further information, please contact : Volker Braun, EVP Head of Global Investor Relations & ESG,volker.braun@evotec.com, Phone +49 (0)40 228 999 338, Mobil +49.(0)40 228 999 338, www.evotec.com interim STATEMENT 9M 2
Evotec SE has released its interim statement for the first nine months of 2024, reporting a slight decrease in group revenues of 1% year-over-year. While the company confirmed a positive business outlook for the full year, it faced challenges with a decrease in gross margin to 11.9% and significant reorganization costs. The Just-Evotec Biologics segment exhibited strong growth, contributing significantly to the overall revenues despite challenges in other segments. Financial results indicate ongoing adjustments and reallocations aimed at stabilizing operations post-cyber-attack and focusing on strategic alliances.
Read more →EVOINTERIM STATEMENT 6M 2024 For further information, please contact: Volker Braun, EVP Head of Global Investor Relations & ESG, volker.braun@evotec.com, M. +49.(0)151.1940 5058, www.evotec.com HIGHLIGHTS } SECOND QUARTER I
Evotec's interim report for the first half of 2024 indicates a considerable net income loss of €115.6 million, contrasted with a positive EBITDA in 2023. The company signed a €250 million syndicated loan to bolster its operations and growth strategies. Despite this, management has revised revenue expectations for FY2024 upwards, forecasting between €790 million and €820 million. However, substantial reorganization costs and continuing adjustments in their financial metrics highlight persistent challenges in operational performance.
Read more →EVO▼ -11.3%on this news· ran to -29% by day 1
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec SE provides guidance update Hamburg, Germany, - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime St
Evotec SE has announced an update to its guidance for the fiscal year 2024, indicating lower expectations for both revenue and adjusted EBITDA. The company forecasts group revenues between 790 - 820 million euros, significantly lowered from its previous guidance of low double-digit percentage growth. R&D expenditures are expected to decrease as well, reflecting a shift in financial strategy. The adjustments are attributed to slower sales order conversions and ongoing margin pressures.
Read more →EVOResults of the Annual General Meeting 2024 Most agenda items adopted with great majority Annual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and D
Evotec SE announced that the majority of agenda items were adopted during the Annual General Meeting 2024 held on June 10. New members Dr Duncan McHale and Wesley Wheeler were elected to the Supervisory Board, replacing outgoing members. The meeting also approved the Remuneration Report 2023 but rejected the discharge of former CEO Dr Werner Lanthaler for the previous financial year. Overall, the event indicated strong shareholder support for the company's strategic direction.
Read more →EVOFor further information, please contact : Volker Braun, EVP Head of Global Investor Relations & ESG, volker.braun@evotec.com, M. +49.(0)40 228 999 338, www.evotec.com interim STATEMENT 3M 2024 HIGHLIGHTS CHALLENGING Q1 W
Evotec SE reported a challenging first quarter for 2024 with group revenues declining by 2% to 208.7 million compared to the same period in 2023. The Shared R&D segment experienced a significant drop in revenues by 23%. However, strong growth in the Just - Evotec Biologics segment, along with a 70% increase in Discovery orders, points to a potential recovery. The company has initiated a reset for profitable growth and established several strategic partnerships in therapeutic development.
Read more →EVOEvotec SE appoints Dr Christian Wojczewski as Chief Executive Officer 23-Apr-2024 / 20:38 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News -
Evotec SE has appointed Dr Christian Wojczewski as its new Chief Executive Officer, effective July 1, 2024. Dr Wojczewski holds a degree in chemistry and has over 20 years of experience, having previously held leadership roles at Mediq and Linde Healthcare. This move follows the retirement of Interim CEO Dr Mario Polywka, who has led the company since January 2024. The announcement aims to ensure a smooth leadership transition for the company.
Read more →EVO▼ -7.8%on this news
Evotec announces CEO transition Hamburg, Germany, - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that CEO Dr Werner Lanthaler has inform
Evotec SE has announced a transition in its leadership, with CEO Dr. Werner Lanthaler resigning for personal reasons. He will continue to provide support to the company's Supervisory Board as a strategic advisor. Dr. Mario Polywka, previously the COO and a member of the Supervisory Board, will serve as the interim CEO. Notably, the company has reaffirmed its guidance for 2023, signaling operational stability.
Read more →EVO▲ +6.6%on this news
For further information, please contact : Volker Braun, SVP Head of Global Investor Relations & ESG, volker.braun@evotec.com, M. +49(0)151.1940 5058, www.evotec.com interim STATEMENT 9M 2023 HIGHLIGHTS 4 CONTINUATION OF
Evotec SE has reported a 14% increase in revenues for the first nine months of 2023, attributed to strong market demand and successful partnerships, despite facing challenges from a cyber-incident that impacted productivity. The company confirmed its full-year 2023 guidance and mid-term goals for 2025. Significant progress was made in pipeline development, particularly with advancements in neurodegeneration treatments and new collaborations aimed at addressing unmet medical needs. Furthermore, Evotec's sustainability efforts were recognized by the approval of their emissions reduction targets by the Science Based Targets initiative.
Read more →EVO▲ +5.7%on this news
For further information, please contact : Volker Braun, SVP Head of Global Investor Relations & ESG, volker.braun@evotec.com, M. +49.(0)151.1940 5058, www.evotec.com HALF-YEAR REPORT 2023 I. MANAGEMENT REPORT 4 NEW AND E
Evotec SE reported a strong revenue growth of 14% to 383.8 million euros in the first half of 2023, driven by high demand and successful partnerships. However, the company faced significant costs due to a cyber-incident, which impacted productivity during Q2. Despite this, Evotec confirmed its financial guidance for the full year 2023, highlighting continued strategic partnerships and progress in drug development. New alliances with Janssen and expansions of existing collaborations with Bristol-Myers Squibb were also noted as positive developments.
Read more →EVO▼ -8.8%on this news
Evotec provides update on financial impact of cyber-attack Hamburg, Germany, - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it is a
Evotec SE has announced an adjustment to its financial guidance for 2023 due to the impact of a recent cyber-attack. Projected Group revenues have been revised down to between 750 and 790 million euros, with unpartnered R&D expectations now at 60 to 70 million euros. EBITDA forecast has also been reduced, expected to reach between 60 and 80 million euros. Despite these challenges, the company's long-term plan, known as Action Plan 2025, maintains its ambition for over 1 billion euros in revenue.
Read more →EVOPage 2 | 12 6. Total positions % of voting rights attached to shares (total of 7.a.) % of voting rights through instruments (total of 7.b.1. + 7.b.2.) Total of both in % (7.a. + 7.b.) Total number of voting rights pursua
BlackRock Asset Management Deutschland AG has disclosed its voting rights associated with shares, indicating a total of 3.29% voting rights attached to shares and an additional 0.28% through instruments. As of June 16, 2023, the total voting rights percentage reached 3.57%. The firm provided information regarding the management and control of these voting rights as mandated by regulatory requirements. This report includes necessary details under the WpHG regulations.
Read more →EVONotification of Major Holdings Page 1 | 11 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name,
The article details the notification of major holdings by BlackRock Asset Management Deutschland AG regarding its shareholdings in Evotec SE. The notification states changes in voting rights associated with the shares, as BlackRock's stake has decreased from 3.70% to 2.22%. Specific voting rights percentages attached to shares and instruments are outlined, showcasing the reporting obligations under the relevant German regulations (WpHG). Additionally, information about the person subject to the notification obligation is provided, emphasizing BlackRock's corporate structure.
Read more →EVOJust - Evotec Biologics enters strategic biosimilars partnership with Sandoz Hamburg, Germany, - Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that Ev
Evotec SE has announced a strategic partnership involving its subsidiary, Just - Evotec Biologics, and Sandoz for the development and manufacturing of biosimilars. This long-term collaboration includes a potential in-licensing of Evotec's proprietary J.DESIGN technology. Evotec is set to receive multi-million dollar upfront payments, with further financial incentives tied to successful development and commercialization progress. The partnership aims to enhance production capabilities through a new facility that Sandoz will build and operate.
Read more →EVOCyber Attack on Evotec 07-Apr-2023 / 15:10 CET/CEST The issuer is solely responsible for the content of this announcement. Hamburg, Germany, - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9,
Evotec SE announced a cyber attack that targeted its IT systems on April 6, 2023. In response, the company proactively shut down its systems and disconnected them from the Internet to protect against potential data breaches and corruption. Currently, Evotec is conducting a review to assess the full scope of the cyber attack and to ensure data integrity moving forward.
Read more →EVO▲ +5.2%on this news
March 2023 Ad hoc release according to Article 17 MAR of the Regulation (EU) No 596/2014 Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership Hamburg, Germany - Evotec SE (Frankfurt Stock Exchan
Evotec SE has announced the expansion and extension of its strategic partnership with Bristol Myers Squibb in the field of neurodegeneration, originally established in 2016. The partnership has been extended for eight years, with the aim of broadening the programme pipeline for neurodegenerative diseases. Evotec will receive a $50 million upfront payment along with additional undisclosed milestone payments and royalties, making the total deal potential reach $4 billion.
Read more →EVOEvotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer 07.02.2023 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Hamburg, Germany, 07 February 2023: Evotec
Evotec SE announced the appointment of Laetitia Rouxel as the new Chief Financial Officer, effective from April 1, 2023. Rouxel succeeds Enno Spillner, who is leaving to pursue new opportunities after contributing significantly to Evotec's growth. The company's management highlighted Rouxel's extensive experience in finance and her potential to help drive future growth. Spillner's departure marks a transition as Evotec positions itself for the next phase of development.
Read more →EVO▼ -5.3%on this news
Notification of Major Holdings | Page 1 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name,
Rowe Price Group, Inc. T. Rowe Price Associates, Inc. 9,37 % 9,37 % T. Rowe Price International Ltd 9. In case of proxy voting according to Sec. 34 (3) WpHG (only in case of attribution of voting rights pursuant to Sec. 34 (1) sent. 1 no. 6 WpHG) Date of general meeting Total pos
Read more →EVO▼ -10.4%on this news
For further information, please contact : Volker Braun, SVP Head of Global Investor Relations & ESG, volker.braun@evotec.com, T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com interim STATEMENT 9M 2022 HIG
For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, volker.braun@evotec.com, T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com 4 multiple new and extended alliances in all areas 4 Paradigm shift in biologics Star
Read more →EVOStimmrechtsmitteilung | Seite 1 3 Hamburg 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Stimmrechtsmitteilung oder Korrektur einer Stimmrechtsmitteilung vom 1. Angaben zum Emittenten Name
X Vollst ndige Kette der Tochterunternehmen, beginnend mit der obersten beherrschenden Person oder dem obersten beherrschenden Unternehmen. Unternehmen Stimmrechte in %, wenn 3% o der h her Instrumente in %, wenn 5% oder h her Summe in %, wenn 5% oder h her -Roland Oetker -ROI Ve
Read more →EVOFor further information, please contact : Volker Braun, SVP Head of Global Investor Relations & ESG, volker.braun@evotec.com, T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com HALF-YEAR REPORT 2022 I. MANA
information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, volker.braun@evotec.com, T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com 4 NEW AND EXTENDED ALLIANCES underline success of GROWTH STRATEGY 4 Acquisition expands capabilities
Read more →EVOEvotec SE reports results of Annual General Meeting 2022 ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY CAMILLA MACAPILI LANGUILLE ELECTED AS NEW MEMBER OF THE SUPERVISORY BOARD; KASIM KUTAY RESIGNS FROM SUPERVISORY
evo_ex991.htm EXHIBIT 99.1 Evotec SE reports results of Annual General Meeting 2022 ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY CAMILLA MACAPILI LANGUILLE ELECTED AS NEW MEMBER OF THE SUPERVISORY BOARD; KASIM KUTAY RESIGNS FROM SUPERVISORY BOARD AUTHORISED CAPITAL
Read more →EVO▼ -6.8%on this news· ran to -18% by day 3
Notification of Major Holdings | Page 1 11 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name,
In case of proxy voting according to Sec. 34 (3) WpHG (only in case of attribution of voting rights pursuant to Sec. 34 (1) sent. 1 no. 6 WpHG) Date of general meeting Total positions (6.) after general meeting % of voting rights attached to shares % of voting rights through inst
Read more →EVONotification of Major Holdings | Page 1 3 Hamburg 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. De
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity: Name % of voting rights (if at least held 3% or more) % of voting rights through instruments (if at least held 5% or more) Total of both (if at least held 5% or more) -N
Read more →EVO▲ +16.4%on this news
For further information, please contact : Volker Braun, SVP Global Head of Investor Relations & ESG, volker.braun@evotec.com, T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com INTERIM STATEMENT Q1 2022 HIG
further information, please contact: Volker Braun, SVP Global Head of Investor Relations & ESG, volker.braun@evotec.com, T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com Strong performance leads to SIGNIFICANT revenue growth Strong momentum in all BUSINESS are
Read more →EVO▲ +16.4%on this news
Evotec and Bristol Myers Squibb extend and expand strategic partnership Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces today that the C
EVOTEC AND BRISTOL MYERS SQUIBB EXTEND AND EXPAND STRATEGIC PARTNERSHIP Evotec and Bristol Myers Squibb extend and expand strategic partnership Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces to
Read more →EVO▼ -7.2%on this news
Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE DATA-DRIVEN PLATFORMS AND TECHNOLO
Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIE
Read more →EVO▼ -15.1%on this news
Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480
evo_ex991.htm EXHIBIT 99.1 Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) announce
Read more →EVOFor further information, please contact: Volker Braun, SVP Global Head of Investor Relations & ESG, volker.braun@evotec.com, T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com INTERIM STATEMENT 9M 2021 HIGH
For further information, please contact: Volker Braun, SVP Global Head of Investor Relations & ESG, volker.braun@evotec.com, T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com 4 Strong operational performance leads to SIGNIFICANT revenue growth 4 Co-owned pipeli
Read more →EVOTable of Contents
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the period ended September 30, 2010 Evotec Aktiengesellschaft (Exact name of registran
Read more →Competitive Position
How EVO ranks across every disease it competes inCompetitive Position is a premium feature
See how EVO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial